Immunogenicity of a Meningococcal B Vaccine during a University Outbreak. - Wikidata - wikimedia - TriplyDB

Immunogenicity of a Meningococcal B Vaccine during a University Outbreak.

Immunogenicity of a Meningococcal B Vaccine during a University Outbreak.

http://www.wikidata.org/entity/Q37192707

about

New vaccines: challenges of discovery Emerging experience with meningococcal serogroup B protein vaccines.Recent Progress in the Prevention of Serogroup B Meningococcal Disease.Does post-implementation vaccine effectiveness data support pre-implementation predictions of 4CMenB utility?Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Portugal.Enhanced protective antibody to a mutant meningococcal factor H-binding protein with low-factor H binding.Serum Bactericidal Antibody Responses of Adults Immunized with the MenB-4C Vaccine against Genetically Diverse Serogroup B Meningococci.Meningococcal serogroup B vaccines: Estimating breadth of coverage.Frequent capsule switching in 'ultra-virulent' meningococci - Are we ready for a serogroup B ST-11 complex outbreak?The next chapter for group B meningococcal vaccines.An unwanted guest: Neisseria meningitidis - carriage, risk for invasive disease and the impact of vaccination with insight on Italy incidence.Serum Bactericidal Antibody Responses of Students Immunized With a Meningococcal Serogroup B Vaccine in Response to an Outbreak on a University Campus.Breadth and Duration of Meningococcal Serum Bactericidal Activity in Health Care Workers and Microbiologists Immunized with the MenB-FHbp Vaccine.Persistence of immunity after vaccination with a capsular group B meningococcal vaccine in 3 different toddler schedules.Meningococcal Antigen Typing System (MATS)-Based Neisseria meningitidis Serogroup B Coverage Prediction for the MenB-4C Vaccine in the United States.Commentary: Impact of meningococcal group B OMV vaccines, beyond their brief.4CMenB vaccine effectiveness: reasons for optimism.Challenges and opportunities for Meningococcal vaccination in the developing world.Cross-protection induced by VA-MENGOC-BC® vaccine.The role of anti-NHba antibody in bactericidal activity elicited by the meningococcal serogroup B vaccine, MenB-4C.Distinct evolutionary patterns of Neisseria meningitidis serogroup B disease outbreaks at two universities in the USA.Global epidemiology of serogroup B meningococcal disease and opportunities for prevention with novel recombinant protein vaccines.Progress toward the global control of Neisseria meningitidis: 21st century vaccines, current guidelines, and challenges for future vaccine development.Potential Coverage of the 4CMenB Vaccine against Invasive Serogroup B Isolated from 2009 to 2013 in the Republic of Ireland

P2860

Q26970823-0271F1F0-CEAC-4FFA-8EC6-F6E2EE091383 Q30234958-E114298C-C599-4EE0-A166-A915366D13A7 Q30235040-3EA634D9-3655-475B-9106-8D08F4499366 Q30235138-AB934AFD-E35F-41CD-816C-75C9B0424529 Q33620864-082A7C7F-36C2-435C-89BA-B7350883E0F6 Q37277250-E710894D-EE8D-4E3F-89C8-483108F5E617 Q37563627-4AB35B8A-3E5A-4F4C-92C2-EBB475F99119 Q37669413-E897F767-1FE4-4C57-9593-64D8A17E02AB Q38674983-84F762A4-C608-42FB-8121-5BA48C81A43A Q38677309-6A71E2F9-1A43-4BE4-9F03-CF88F4253694 Q38775024-4293B93D-7A88-42D0-9451-8B607B256002 Q40172533-4AB75972-1151-4729-99AA-FBF833D3D920 Q40178578-35B95FF0-8E22-48C7-82F9-E882FEC42D5D Q42678551-B5D78306-44BC-4441-BC10-605BE7EB7BD5 Q45824896-78B55E03-39A3-4EA6-BF56-6CB35048E784 Q46280467-DCA0BBA6-FA6D-456C-A8DB-29C78FB90861 Q47352260-5CDED3C2-EDDE-4559-9AAF-B36D8CD52C5C Q49377063-B4782148-B445-4548-8D95-75DE4187247B Q50116274-C1080BF4-E1E7-49FA-A613-80198B90598A Q50922458-0FDE0656-F3E1-45E9-949F-860BD44A16C4 Q52332492-45173425-E095-410A-8DF9-8EF29969B0B0 Q54233532-6B8DECA1-E155-4286-A031-B420A663FBD3 Q54255446-88135731-3E8A-4CB3-A0F7-664F39CB2013 Q57970428-A07424A2-A6E2-48CD-926C-EAC810EFD69A

P2860

Immunogenicity of a Meningococcal B Vaccine during a University Outbreak.

http://www.wikidata.org/entity/Q37192707

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on July 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Immunogenicity of a Meningococcal B Vaccine during a University Outbreak.

@en

Immunogenicity of a Meningococcal B Vaccine during a University Outbreak.

@nl

type

label

Immunogenicity of a Meningococcal B Vaccine during a University Outbreak.

@en

Immunogenicity of a Meningococcal B Vaccine during a University Outbreak.

@nl

prefLabel

Immunogenicity of a Meningococcal B Vaccine during a University Outbreak.

@en

Immunogenicity of a Meningococcal B Vaccine during a University Outbreak.

@nl

P1433

Q37192707-9BF1FEB9-0868-4A85-98C5-9B2763250EAE

P1476

Q37192707-9CA13FDB-0C3B-402F-BFD6-6CEC000C1450

P2093

Q37192707-155568A2-8DE4-4F00-B366-831298D75EAA

Q37192707-3204480D-F54F-41D8-9CE0-0109E198DD8B

Q37192707-5C6FBFC5-4BA1-4C85-BD1D-DAD33819DB00

Q37192707-96E58EE8-136D-47F7-9730-CEAFBACB6792

Q37192707-B0D64E05-79FF-42CD-BA98-8AB666EBEFD0

Q37192707-BABA16B6-DB9B-4464-81D3-FEFBE1A6E1B9

Q37192707-C75552BE-D1B8-41F1-A5EB-E042F7DAA06F

Q37192707-E197C7AA-B386-4FCF-8299-9BC7D41F83FF

Q37192707-E8F04E3D-13DB-41D2-85DA-0BEBC38E8772

Q37192707-F15BC4E2-0C26-4575-804E-7A3535BDB061

P2860

Q37192707-0C20443A-A9BD-4316-B9A3-E52F78BDD619

Q37192707-0CE67E6F-D073-4C7F-94A8-3F61491A821D

Q37192707-119A0D14-7B61-4881-B98B-C06485C96097

Q37192707-367F8A3F-4B87-4BA6-B927-CC07878F76D4

Q37192707-3DD0456E-F682-475C-A69C-1F4BED448190

Q37192707-40B2C14E-7757-458D-969F-B1E916872B0E

Q37192707-4B75730A-B4F9-497A-98FC-50988A536EF4

Q37192707-4C4D1E6E-57A1-4A26-9423-F2DC5A0A7A35

Q37192707-53B0E8EE-0BEB-454E-B7B3-F13F5EACC7AD

Q37192707-5DE03DB5-DB6B-49E7-9949-0FD58FDEC613

P304

Q37192707-3C80C00E-F98A-4917-91C1-1B169B55F11A

P31

Q37192707-A962B5C9-328E-4DFA-BF6E-246CFA6AD165

P356

Q37192707-783458EB-CD0B-4F57-B5E0-D29B56FA5897

P407

Q37192707-338D8D05-8E8A-452C-A249-ECF4B21CC46A

P433

Q37192707-FFFC5B12-16B8-4CA8-96D2-6B59292D3B71

P478

Q37192707-C679552F-9AB0-4985-86E9-8D0657886244

P50

Q37192707-DB9DDC45-1E35-45C5-84D6-BBBE3261B657

Q37192707-F33128FD-426A-4889-A326-C46E8EE88804

P577

Q37192707-7A2A9B27-1D92-413A-BFD2-36E28F9B3422

P698

Q37192707-418619EB-F5B3-4848-B75E-606E593CF4AD

P932

Q37192707-46DB0F5C-9171-442D-A374-E090759DF4CE

P356

P1433

The New England Journal of Medicine

P1476

Immunogenicity of a Meningococcal B Vaccine during a University Outbreak.

@en

P2093

Adel A F Mahmoud

http://www.w3.org/2001/XMLSchema#string

Alexander Ploss

http://www.w3.org/2001/XMLSchema#string

Brigitte L Heller

http://www.w3.org/2001/XMLSchema#string

Jamie Findlow

http://www.w3.org/2001/XMLSchema#string

Julian Wolfson

http://www.w3.org/2001/XMLSchema#string

Nicole E Basta

http://www.w3.org/2001/XMLSchema#string

Peter Johnsen

http://www.w3.org/2001/XMLSchema#string

Robin Izzo

http://www.w3.org/2001/XMLSchema#string

Sarah Hanna

http://www.w3.org/2001/XMLSchema#string

Xilian Bai

http://www.w3.org/2001/XMLSchema#string

P2860

Vaccination with a multicomponent meningococcal B vaccine in prevention of disease in adolescents and young adults

MATS: Global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccine

Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup b, strain 44/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine.

Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines.

Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group.

Meningococcal surrogates of protection--serum bactericidal antibody activity.

First Use of a Serogroup B Meningococcal Vaccine in the US in Response to a University Outbreak.

Susceptibility of Meningococcal Strains Responsible for Two Serogroup B Outbreaks on U.S. University Campuses to Serum Bactericidal Activity Elicited by the MenB-4C Vaccine

Interlaboratory standardization of the sandwich enzyme-linked immunosorbent assay designed for MATS, a rapid, reproducible method for estimating the strain coverage of investigational vaccines

A multi-component meningococcal serogroup B vaccine (4CMenB): the clinical development program.

P304

220-228

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1514866

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

375

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27468058

http://www.w3.org/2001/XMLSchema#string

P932

4992664

http://www.w3.org/2001/XMLSchema#string